Rocket Pharmaceuticals, Inc. (RCKT)

The FDA accepted Rocket Pharmaceuticals' BLA resubmission for KRESLADI™ for LAD-I. The FDA lifted a clinical hold on the Phase 2 trial of RP-A501 for Danon Disease. The company withdrew its FDA application for RP-L102 gene therapy. The CFO resigned in August. The company cut headcount and realigned its pipeline in July. RCKT stock has experienced significant volatility.

As a clinical-stage biopharmaceutical company, Rocket Pharmaceuticals does not have established demand seasonality for its products and services, as its products are not yet commercialized.

Rocket Pharmaceuticals is a biopharmaceutical company focused on developing gene therapies for rare pediatric diseases, utilizing lentiviral and adeno-associated viral vector platforms. Its pipeline includes RP-A501 for Danon Disease, KRESLADI™ (RP-L201) for severe Leukocyte Adhesion Deficiency-I (LAD-I), RP-L102 for Fanconi Anemia, RP-L301 for Pyruvate Kinase Deficiency, and RP-A601 PKP2-ACM and AAV BAG3-DCM for cardiovascular conditions.

Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, United States. The company has potential future market reach in Europe due to the Orphan Medicinal Product Designation from the European Commission for RP-A601.

Rocket Pharmaceuticals generally holds a "Hold" consensus rating from Wall Street analysts. MarketBeat's evaluation placed Rocket Pharmaceuticals higher than 98% of other companies in the medical sector. Stock events such as the withdrawal of an FDA application, CFO resignation, and headcount reduction could indirectly influence investor and industry perception.

Institutional investors own a significant portion (85.78%) of Rocket Pharmaceuticals' stock, while insiders hold 9.68%. Vanguard Personalized Indexing Management LLC has sold shares of the company.